The purpose of this clinical trial is to evaluate the effects of adding CAN-2409 + prodrug for stage III/IV NSCLC patients who are on standard of care first line immune checkpoint inhibitor (ICI) treatment with evidence that the clinical response is inadequate. CAN-2409 is a viral immunotherapy approach that induces tumor-infiltrating T-cells and a consequent PD-L1 up-regulation. A combination of CAN-2409 added to standard of care (SOC) checkpoint inhibitors may lead to improved long-term outcomes for patients with NSCLC who have suboptimal response to ICI therapy.

开始日期2020-10-13

申办/合作机构

Candel Therapeutics, Inc.

[+1]

NCT03603405

/ Recruiting临床1/2期IIT

Phase I-II Study Evaluating HSV-tK + VALACYCLOVIR GENE THERAPY Combination with Radiotherapy and Chemotherapy for Newly Diagnosed Anaplastic Astrocytoma and Glioblastoma Multiforme.

Study to assess the safety and efficacy of HSV-tk (gene therapy), valacyclovir, radiotherapy and chemotherapy in newly diagnosed glioblastoma multiforme (GBM) or anaplastic astrocytoma (AA).

开始日期2018-02-28

申办/合作机构

The Methodist Hospital Research Institute

NCT03576612

/ Completed临床1期

Phase I Study of Neoadjuvant GMCI Plus Immune Checkpoint Inhibitor Combined With Standard of Care for Newly Diagnosed High-Grade Gliomas

The purpose of this phase I trial is to test the safety of combining GMCI, an immunostimulator, plus nivolumab, an immune checkpoint inhibitor (ICI), with standard of care radiation therapy, and temozolomide in treating patients with newly diagnosed high-grade gliomas.
Gene Mediated Cytotoxic Immunotherapy (GMCI) involves the use of aglatimagene besadenovec (AdV-tk) injection into the tumor site and oral valacyclovir to kill tumor cells and stimulate the immune system. Nivolumab is an immune checkpoint inhibitor that may also stimulate the immune system by blocking the PD-1 immune suppressive pathway. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors and temozolomide is a chemotherapy drug that kills tumor cells. Giving GMCI, nivolumab, radiation therapy, and temozolomide may work better in treating patients with high-grade gliomas

开始日期2018-02-27

申办/合作机构

Candel Therapeutics, Inc.

[+2]

100 项与 Aglatimagene besadenovec 相关的临床结果

登录后查看更多信息

100 项与 Aglatimagene besadenovec 相关的转化医学

登录后查看更多信息

100 项与 Aglatimagene besadenovec 相关的专利（医药）

登录后查看更多信息

项与 Aglatimagene besadenovec 相关的文献（医药）

2025-02-01·Biochemical genetics

The Combinatorial Effect of Ad-IL-24 and Ad-HSV-tk/GCV on Tumor Size, Autophagy, and UPR Mechanisms in Multiple Myeloma Mouse Model

Article

作者: Hosseini, Seyed Younes ; Irani, Shiva ; Abdoli, Asghar ; Baesi, Kazem ; Poorghobadi, Shima ; Sadat, Seyed Mehdi

Multiple myeloma is a type of malignant neoplasia whose treatment has changed over the past decade. This study aimed to investigate the effects of combination of Adenovector-carrying interleukin-24 and herpes simplex virus 1 thymidine kinase/ganciclovir on tumor growth, autophagy, and unfolded protein response mechanisms in mouse model of multiple myeloma. Six groups of mice, including Ad-HSV-tk/GCV, Ad-IL-24, Ad-HSV-tk/IL-24, Ad-GFP, and positive and negative controls, were investigated, and each group was injected every 72 h. The tumor size was measured several times. The expression of LC3B evaluated through western blotting and ASK-1, CHOP, Caspase-3, and ATF-6 genes in the UPR and apoptosis pathways were also analyzed by the quantitative polymerase chain reaction (qPCR) method. The present results showed that the injection of Ad-HSV-tk/GCV, Ad-HSV-tk/IL-24, and metformin reduced the tumor size. The expression of LC3B was significantly higher in the treatment groups and positive control groups compared to the negative control group. The expression of CHOP, caspase-3, and ATF-6 genes was significantly higher in the Ad-IL-24 group compared to the other treatment groups. Besides, the ASK-1 expression was significantly lower in the Ad-IL-24 group as compared to the other groups. Overall, the results indicated that the presence of the HSV-tk gene in the adenovectors reduced the size of tumors and induced autophagy by triggering the expression of LC3B protein. The presence of the IL-24 might affect tumor growth but not as much the therapeutic effect of HSV-tk. Furthermore, the results indicated that co-administration of IL-24 and HSV-tk had no synergistic effect on tumor size control.

2025-02-01·Cancer research communications

Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy

Article

作者: Richardson, Erin ; Li, Zhi ; Withers, David R. ; Tak, Paul P. ; Willis, Claire ; Idris, Suaad ; Barone, Francesca ; Diers, Anne R. ; Guo, Qiuchen

Abstract:

CAN-2409 is a replication-defective adenovirus that delivers the herpes simplex virus–thymidine kinase gene to infected cells. Intratumoral administration of CAN-2409, followed by prodrug, results in the formation of a toxic metabolite able to induce immunogenic cell death, exposure of tumor-associated antigens, and activation of local and systemic immune responses. We used a dynamic labeling model with MC38 tumor cells implanted in photoconvertible Kaede mice. Violet light was used to label the tumor microenvironment (TME), distinguishing retained versus newly entering cells and allowing real-time monitoring of immune compartment changes within tumors. Administration of CAN-2409 + prodrug led to control of tumor growth and significantly increased effector CD8+ T-cell responses. Photolabeling of the TME revealed that rather than enhancing recruitment of T cells to the tumor, CAN-2409 altered the TME whereby newly entering and retained CD8+ T cells were significantly more proliferative. CAN-2409 supported reinvigoration of tumor-associated antigen–specific CD8+ T cells and expansion of regulatory T cells of an altered phenotype. Moreover, the combination of CAN-2409 + prodrug and anti–CTLA-4 antibody treatment further improved control of tumor growth, in part by the enhanced CD8+ T-cell–mediated effector function and diminished regulatory T cell–mediated immunosuppression. Collectively, these data defined at least two temporally distinct pathways underpinning the mechanism of action of CAN-2409 that overcome cell exhaustion and decrease immune suppression. The results also support the rationale for future clinical trials of CAN-2409 treatment combined with anti–CTLA-4 antibody therapy.

Significance::

This study utilized a novel photoconvertible mouse tumor model to track immune cell trafficking upon treatment with an investigational viral immunotherapy (CAN-2409), revealing enhanced T-cell responses after viral immunotherapy associated with local proliferation of T cells within tumors that could further enhance antitumor efficacy in combination with immune checkpoint inhibitors. These findings define temporally and spatially distinct interactions of immune cells that could be harnessed by novel therapeutics.

2023-10-03·Expert opinion on biological therapy

Oncolytic virotherapies for pediatric tumors

Review

作者: Atchley, Travis J ; Johnston, James M ; Laskay, Nicholas Mb ; Markert, James M ; Gross, Evan G ; Estevez-Ordonez, Dagoberto ; Hamo, Mohammad A

INTRODUCTION:

Many pediatric patients with malignant tumors continue to suffer poor outcomes. The current standard of care includes maximum safe surgical resection followed by chemotherapy and radiation which may be associated with considerable long-term morbidity. The emergence of oncolytic virotherapy (OVT) may provide an alternative or adjuvant treatment for pediatric oncology patients.

AREAS COVERED:

We reviewed seven virus types that have been investigated in past or ongoing pediatric tumor clinical trials: adenovirus (AdV-tk, Celyvir, DNX-2401, VCN-01, Ad-TD-nsIL-12), herpes simplex virus (G207, HSV-1716), vaccinia (JX-594), reovirus (pelareorep), poliovirus (PVSRIPO), measles virus (MV-NIS), and Senecavirus A (SVV-001). For each virus, we discuss the mechanism of tumor-specific replication and cytotoxicity as well as key findings of preclinical and clinical studies.

EXPERT OPINION:

Substantial progress has been made in the past 10 years regarding the clinical use of OVT. From our review, OVT has favorable safety profiles compared to chemotherapy and radiation treatment. However, the antitumor effects of OVT remain variable depending on tumor type and viral agent used. Although the widespread adoption of OVT faces many challenges, we are optimistic that OVT will play an important role alongside standard chemotherapy and radiotherapy for the treatment of malignant pediatric solid tumors in the future.

135

项与 Aglatimagene besadenovec 相关的新闻（医药）

2025-07-09

·ir.candeltx.com

Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution

NEEDHAM, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that the Company was added to multiple Russell indexes as part of the 2025 Russell US Indexes annual reconstitution, which became effective at the open of the U.S. equity markets on June 30, 2025. Candel was added to the Russell 2500 Value® Index, Russell Small Cap Value® Index, Russell 2000 Value® Index, Russell Microcap Value® Index, and Russell 3000E® Value Index. Additionally, the Company maintained its membership in the broad-market Russell 3000® Index, which it first joined in 2024. “Candel’s inclusion across multiple Russell Value® indexes represents an important milestone that reflects the significant progress we have made in advancing our clinical programs and discovery efforts focused on harnessing the immune system to fight cancer,” said Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer of Candel. “These inclusions come as we enter a transformative period for our company, with preparations underway for our potential submission of a Biologics License Application and pre-commercialization efforts for CAN-2409 in intermediate-to-high-risk localized prostate cancer, and as we continue advancing our innovative multimodal immunotherapy platform across various solid tumors. These index inclusions will allow us to further engage with the investment community as we work to develop novel immunotherapies for patients with significant unmet medical needs.” Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to data as of the end of June 2024, approximately $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to FTSE Russell, the global index provider. The annual reconstitution of the Russell US indexes captures the 4,000 largest US stocks as of April 30, ranking them by total market capitalization. About Candel Therapeutics Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform. The Company recently completed successful phase 2a clinical trials of CAN-2409 in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal phase 3 clinical trial of CAN-2409 in localized prostate cancer, conducted under a Special Protocol Assessment (SPA) agreed with the U.S. Food and Drug Administration (FDA). CAN-2409 plus prodrug (valacyclovir) has been granted Fast Track Designation by the FDA for the treatment of PDAC, stage III/IV NSCLC in patients who are resistant to first line PD-(L)1 inhibitor therapy and who do not have activating molecular driver mutations or have progressed on directed molecular therapy and localized primary prostate cancer. The FDA also granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CAN-2409 for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease and Orphan Drug Designation to CAN-2409 for the treatment of PDAC. CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma (rHGG). Initial results were published in Nature and CAN-3110 received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. For more information about Candel, visit: www.candeltx.com About FTSE Russell FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $18.1 trillion is benchmarked to FTSE Russell indexes. Leading asset owners, asset managers, ETF providers and investment banks choose FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives. A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering. FTSE Russell is wholly owned by the London Stock Exchange Group. For more information, visit www.lseg.com/en/ftse-russell. Forward-Looking Statements This press release includes certain disclosures that contain “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs, expectations regarding the submission of the Biologics License Application for CAN-2409 in intermediate-to-high-risk localized prostate cancer; expectations regarding the therapeutic benefit of the Company’s platforms, including the ability of its platforms to improve overall survival and/or disease-free survival of patients living with difficult to treat, solid tumors; and expectations regarding the potential benefits conferred by the Company’s inclusion in the Russell indexes. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company’s programs; that final data from the Company’s preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company’s ability to efficiently discover and develop product candidates; the Company’s ability to obtain and maintain regulatory approval of product candidates; the Company’s ability to maintain its intellectual property; the implementation of the Company’s business model, including strategic plans for the Company’s business and product candidates; and other risks identified in the Company’s filings with the U.S. Securities and Exchange Commission (SEC), including the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, each as filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Investor Contact: Theodore Jenkins VP, Investor Relations and Business Development Candel Therapeutics, Inc. tjenkins@candeltx.com Media Contact: Ben Shannon ICR Healthcare CandelPR@icrhealthcare.com

临床2期免疫疗法快速通道孤儿药临床1期

2025-06-24

·ir.candeltx.com

Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock

NEEDHAM, Mass., June 24, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, has agreed to sell approximately 3.2 million shares of its common stock (Common Stock) to a select group of accredited investors in a registered direct offering (the Offering), at a price per share of $4.67. The Offering is expected to close on June 25, 2025, subject to the satisfaction of customary closing conditions. Gross proceeds from the Offering are expected to be approximately $15.0 million, before deducting offering-related expenses payable by the Company. The investors in the Offering include existing healthcare-focused institutional investors, executive officers, and members of the Company’s Board of Directors. “We are pleased to strengthen our financial position with the resources intended to support pre-commercialization and launch readiness activities for CAN-2409 in prostate cancer, pending regulatory approval, as well as other key corporate purposes,” commented Paul Peter Tak, M.D., Ph.D., FMedSci, President and CEO of Candel. “The successful completion of this offering reflects strong confidence from both investors and insiders in our innovative approach to treating intractable tumors and in our overall corporate strategy. We continue to be strategic in pursuing funding that we believe best aligns with our priorities, and continue to focus on disciplined capital allocation, in an effort to maximize value creation, while advancing our mission to transform the treatment landscape for patients with cancer.” The Company intends to use the net proceeds from the Offering to complete critical launch readiness, medical affairs and pre-commercialization activities, while preparing for submission of a Biologics License Application for CAN-2409 in prostate cancer expected in the fourth quarter of 2026, and for general corporate purposes. The shares of Common Stock are being offered pursuant to a shelf registration statement that was previously filed by the Company with the U.S. Securities and Exchange Commission (the SEC) on August 5, 2022 (File No. 333-266605) and declared effective by the SEC on August 12, 2022. The Offering is being made only by means of the written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement containing additional information relating to the Offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Candel Therapeutics Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform. The Company recently completed successful phase 2a clinical trials of CAN-2409 in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal phase 3 clinical trial of CAN-2409 in localized prostate cancer, conducted under a Special Protocol Assessment (SPA) agreed with the U.S. Food and Drug Administration (FDA). CAN-2409 plus prodrug (valacyclovir) has been granted Fast Track Designation by the FDA for the treatment of PDAC, stage III/IV NSCLC in patients who are resistant to first line PD-(L)1 inhibitor therapy and who do not have activating molecular driver mutations or have progressed on directed molecular therapy and localized primary prostate cancer. The FDA also granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CAN-2409 for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease and Orphan Drug Designation to CAN-2409 for the treatment of PDAC. CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma (rHGG). Initial results were published in Nature and CAN-3110 received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. For more information about Candel, visit: www.candeltx.com Forward-Looking Statements Certain statements in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events and include statements regarding the Company’s future operating performance and goals; the expected completion, timing and size of the Offering; the anticipated use of proceeds of the Offering; express or implied statements regarding the timing and advancement of current and future development programs; expectations regarding the therapeutic benefit of the Company’s platforms, including the ability of its platforms to improve overall survival and/or disease-free survival of patients living with difficult to treat, solid tumors; and expectations regarding cash runway and expenditures. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company’s programs; that final data from the Company’s preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company’s ability to efficiently discover and develop product candidates; the Company’s ability to obtain and maintain regulatory approval of product candidates; the Company’s ability to maintain its intellectual property; the implementation of the Company’s business model, including strategic plans for the Company’s business and product candidates; that the Company may be unable to complete the Offering due to failure to satisfy closing conditions or for other reasons; that events may arise in the future that require the proceeds to be spent in ways other than anticipated; and other risks identified in the Company’s filings with the U.S. Securities and Exchange Commission (SEC), including the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, each as filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Investor Contact: Theodore Jenkins VP, Investor Relations and Business Development Candel Therapeutics, Inc. tjenkins@candeltx.com Media Contact: Ben Shannon ICR Healthcare CandelPR@icrhealthcare.com

免疫疗法快速通道临床2期孤儿药临床1期

2025-06-17

·Firstwordpharma

Immuneering touts strong survival in pancreatic cancer trial

Immuneering, one of several small biotechs aiming to crack the stubborn challenge of pancreatic cancer, unveiled new results for its experimental oral MEK inhibitor atebimetinib (IMM-1-104). Yet despite the company describing the data as "exceptional," its stock was down more than 14% on Tuesday.The ongoing Phase IIa trial is testing atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) in newly diagnosed pancreatic cancer patients. Data from 34 participants at the 320 mg once-daily dose showed a 94% overall survival (OS) rate at six months, according to the company, which noted that survival rates for these patients would typically be 67% on standard care treatment alone.The data also showed that 72% of patients had no disease progression at six months, well above the historical benchmark of 44%. Neither the median OS or progression-free survival times had been reached at the May 26 data cutoff, the company said.Overall response of 39%An overall response rate (ORR) of 39% and disease control rate of 81% were observed across the 240-mg and 320-mg dose levels, with the company noting "many patients [had] deepening, durable regressions" and there were "multiple examples of individual lesions rendered undetectable." These compare with historic rates of 23% and 48%, respectively, for standard care.Immuneering said atebimetinib continued to demonstrate a "markedly favourable tolerability profile," with no Grade 3 or higher adverse events observed in most categories commonly seen with standard chemotherapy.These findings build on earlier data from January, when the drug combination showed a 43% ORR in seven first-line patients – nearly double the rate seen in a Phase III trial that had led to approval of the current standard treatment combination (see – Spotlight On: Immuneering latest biotech to report progress in pancreatic cancer).Chief Medical Officer Igor Matushansky said the new data "clearly establish atebimetinib's potential as a more durable and better tolerated MEK inhibitor positioned to help patients both live longer and live better." The company is moving to expand enrollment to about 50 patients in the current study arm.Pivotal study in 2026Looking ahead, Immuneering plans to seek regulatory feedback on pivotal study plans in the fourth quarter and initiate a randomised pivotal trial of atebimetinib plus mGnP in 2026. Additional atebimetinib combination arms are expected to be initiated in 2026 as well.Several biotechs are pursuing different approaches in the space, including Candel Therapeutics with its oncolytic virus CAN-2409 and Revolution Medicines, which began a Phase III trial of its pan-RAS inhibitor daraxonrasib (RMC-6236) last October with primary completion targeted for mid-2026.

临床2期临床结果临床3期

100 项与 Aglatimagene besadenovec 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15074

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
局限性前列腺癌	临床3期	美国	Candel Therapeutics, Inc.	2011-09-01
转移性非小细胞肺癌	临床2期	美国	NYU Langone Health	2020-10-13
转移性非小细胞肺癌	临床2期	美国	Candel Therapeutics, Inc.	2020-10-13
复发性前列腺癌	临床2期	美国	Candel Therapeutics, Inc.	2016-05-01
复发性前列腺癌	临床2期	墨西哥	Candel Therapeutics, Inc.	2016-05-01
胰腺腺癌	临床2期	美国	Candel Therapeutics, Inc.	2015-10-01
胰腺腺癌	临床2期	墨西哥	Candel Therapeutics, Inc.	2015-10-01
多形性胶质母细胞瘤	临床2期	美国	Candel Therapeutics, Inc.	2007-03-01
高级别胶质瘤	临床2期	美国	Candel Therapeutics, Inc.	2007-03-01
乳腺癌	临床1期	美国	Candel Therapeutics, Inc.	2013-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01436968 (Phase 3, ASCO2025)	临床3期	局限性前列腺癌	745	CAN-2409+prodrug	憲遞積鏇壓膚網糧糧餘(積鑰範醖艱顧壓壓艱鹹) = 遞範鹹壓觸網鏇鑰衊繭構顧願鬱鬱觸顧觸築構 (積蓋鹹鏇積艱鹹夢餘鹹 )	积极	2025-05-30
				Placebo+prodrug	憲遞積鏇壓膚網糧糧餘(積鑰範醖艱顧壓壓艱鹹) = 積網築鹹遞醖觸壓鹹膚構顧願鬱鬱觸顧觸築構 (積蓋鹹鏇積艱鹹夢餘鹹 )
NCT04495153 (GlobeNewswire) 人工标引	临床2期	晚期非小细胞肺癌	46	CAN-2409 (cohort 1 and 2)	鑰醖願醖製壓齋壓範遞(淵鑰鹹夢窪範艱簾積願) = 餘衊餘窪窪簾壓夢廠膚選蓋繭製鹽鹽鹽鬱鏇齋 (範鏇壓蓋構觸願顧範鑰 )	积极	2025-03-26
				CAN-2409 (cohort 2)	鑰醖願醖製壓齋壓範遞(淵鑰鹹夢窪範艱簾積願) = 製憲遞鹽網網繭窪醖襯選蓋繭製鹽鹽鹽鬱鏇齋 (範鏇壓蓋構觸願顧範鑰 )
NCT02446093 (PaTK02, Company_Website) 人工标引	临床2期	胰腺癌新辅助	13	CAN-2409 + valacyclovir + SoC	顧鹹廠鑰獵鹽築襯鏇網(築衊範餘艱壓鬱衊淵範) = 糧夢憲醖鹹淵窪觸壓範構鹽襯顧構獵觸獵觸鹹 (積衊鹽餘餘積鑰鏇壓製 ) 更多	积极	2025-02-25
				SoC	顧鹹廠鑰獵鹽築襯鏇網(築衊範餘艱壓鬱衊淵範) = 艱齋獵鹽獵繭鬱衊簾鑰構鹽襯顧構獵觸獵觸鹹 (積衊鹽餘餘積鑰鏇壓製 ) 更多
NCT01436968 (PipelineReview) 人工标引	临床3期	前列腺癌	745	CAN-2409 plus Standard of care external beam radiation therapy	獵鏇餘築醖願廠鹹顧築(製願壓膚簾鏇餘鏇襯簾): HR = 0.7, P-Value = 0.0155 达到更多	积极	2024-12-11
				Standard of care external beam radiation therapy
NCT04495153 (ASCO2024) 人工标引	临床2期	非小细胞肺癌	73	CAN-2409 + valacyclovir	顧網遞淵鑰網築鹹鑰糧(築廠淵窪膚積齋願顧鏇) = 憲鏇鹹糧觸繭築製鏇蓋範簾膚襯製鏇遞淵壓鑰 (衊鹹醖襯醖繭鏇鹹糧醖, 14.3 ~ NA) 更多	积极	2024-05-24
				CAN-2409 + valacyclovir (C1, stable disease)	顧網遞淵鑰網築鹹鑰糧(築廠淵窪膚積齋願顧鏇) = 構餘衊糧憲願獵鏇製遞範簾膚襯製鏇遞淵壓鑰 (衊鹹醖襯醖繭鏇鹹糧醖 )
NCT02446093 (PaTK02, Biospace) 人工标引	临床2期	胰腺癌	13	CAN-2409+valacylovir or acyclovir+chemoradiation or SBRT	淵廠範選蓋鏇網糧壓憲(顧顧淵廠醖積蓋憲積鏇) = none 蓋艱鹽選憲壓築顧獵壓 (窪遞顧憲廠積憲餘鏇艱 )	积极	2024-04-04
				chemoradiation or SBRT
NCT00589875 (BrTK02, CTgov)	临床2期	多形性胶质母细胞瘤 \| 高级别胶质瘤	52	Radiation therapy+Temozolomide+Valacyclovir+CAN-2409	鬱鏇齋獵齋築廠鹹範製 = 蓋願網鹹選艱鏇積鏇齋鏇壓鹽積觸選範願鏇鑰 (夢窪繭蓋觸夢壓鑰襯築, 築範構顧壓夢範構獵願 ~ 鹹遞繭選積鏇顧網廠簾) 更多	-	2024-04-03
NCT02446093 (PaTK02, SITC2023)	临床2期	局部晚期胰腺腺癌新辅助 soluble granzymes B \| IL-10 \| IFNÎ³	19	CAN-2409+prodrug	繭遞襯鏇簾製製膚淵鏇(鑰範鏇獵製淵選窪窪願) = 膚願壓築製製鏇餘廠觸鬱糧簾窪醖壓構廠顧構 (憲製遞醖築蓋構鑰積鏇 ) 更多	积极	2023-11-02
				CAN-2409+Prodrug (Standard of care (SOC) chemoradiation (CR) and surgery)	繭遞襯鏇簾製製膚淵鏇(鑰範鏇獵製淵選窪窪願) = 蓋構壓願繭醖窪積餘選鬱糧簾窪醖壓構廠顧構 (憲製遞醖築蓋構鑰積鏇 ) 更多
NCT04495153 (Corporate Publications) 人工标引	临床2期	非小细胞肺癌二线	40	CAN-2409+valacyclovir+immune checkpoint inhibitor	夢壓簾窪夢壓憲鬱鏇鑰(鹹鑰鹹觸鏇築願構鹹膚) = 襯鬱憲淵蓋鑰壓夢鏇繭鬱範鑰構膚衊壓鏇鏇鹽 (願鏇膚選鹹鏇積選壓鬱 ) 更多	积极	2023-09-26
NCT03576612 (SITC 12022 \| SITC 22022) 人工标引	临床1期	高级别胶质瘤一线	41	valacyclovir+CAN-2409+nivolumab (patients with methylated MGMT promoter undergoing gross total resection (GTR))	願獵範齋選選觸鑰範衊(顧憲網網鹽積鹹願鏇齋) = 遞獵構鏇構鹹糧網夢襯鬱鹽鏇製窪衊觸廠鏇鹹 (鏇醖鏇築壓憲窪願遞簾 )	积极	2022-11-01
				valacyclovir+CAN-2409+nivolumab (patients with methylated MGMT promoter undergoing sub-total resection (STR))	願獵範齋選選觸鑰範衊(顧憲網網鹽積鹹願鏇齋) = 壓簾窪壓憲憲顧鑰餘鏇鬱鹽鏇製窪衊觸廠鏇鹹 (鏇醖鏇築壓憲窪願遞簾 )